Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03332069
Other study ID # LACC-OT
Secondary ID
Status Recruiting
Phase Phase 3
First received August 27, 2017
Last updated November 3, 2017
Start date January 9, 2014
Est. completion date July 31, 2020

Study information

Verified date November 2017
Source University of Witwatersrand, South Africa
Contact Carrie A Minnaar, PhD student
Phone +27721234292
Email cazzminn1@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase III randomised clinical trial. The aim is to investigate the clinical effects of the addition of modulated electro-hyperthermia (mEHT) to standard treatment protocols (chemoradiotherapy, CRT) for Human Immunodeficiency Virus (HIV) positive and negative locally advanced cervical cancer patients (LACC). SAMPLE: The investigators aim to enrol 236 HIV negative and HIV positive women with LACC, FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) Stages IIB (distil) to stage III. Participants will be randomly assigned to a control group (N=118) and a study group (N=118). METHODOLOGY: Randomisation is based on age, stage and HIV. Participants from both groups will receive the standard treatment for cervical cancer at the hospital at the Charlotte Maxeke Johannesburg Academic Hospital in South Africa: Up to three doses of 80mg/m2 cisplatin, administered three weeks apart; 50Gy external beam radiation (EBR) in fractions of 2Gy; Three doses of 8Gy High Dose Rate (HDR) brachytherapy. The study group will have two 55 minute mEHT treatments per week, at 130W, directly before the EBR using the EHY 2000 Device. OUTCOMES: 1) Determine the local disease control after treatment at 6 months using a Positron Emission Tomography (PET) and computerised tomography (CT) scans. 2) Determine the progression-free survival (PFS) at 6, 12, 18 and 24 months after the last treatment date. PFS will be assessed in all registered participants, regardless of completion (Intent to Treat-ITT) as well as only in the subset of participants who complete the prescribed CRT. 3) Overall survival at two years will be assessed. 4) To evaluate the adverse events associated with mEHT. 5) The effect of mEHT on chemotherapy and radiotherapy tolerability and toxicity will be evaluated. 6) The quality of life of enrolled participants will be assessed before, at 6 weeks, and at 3, 6, 9, 12, 18 and 24 months after completion of therapy using the EORTC (European Organisation for Research and Treatment of Cancer) and EuroQoL forms. 7) To evaluate the economic viability of the addition of mEHT to standard treatment protocols for LACC. 8) The effect, if any, of mEHT treatments on the HIV disease status of HIV positive patients will be assessed by the presence of Autoimmune Deficiency Syndrome (AIDS) defining illnesses before and after treatment. 9) The cancer recurrence patterns will be described and compared in all the participants.


Recruitment information / eligibility

Status Recruiting
Enrollment 236
Est. completion date July 31, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Participants (who have been adequately clinically staged by standard clinical guidelines) with biopsy proven primary, untreated, histologically confirmed invasive squamous and aden-squamous cell carcinoma of the uterine cervix, FIGO (Fédération Internationale de Gynécologie et d'Obstétrique) stages advanced IIB (invasion of the distal half of the parametrium), IIIA and IIIB.

2. HIV positive participants will be accepted.

3. The following laboratory tests will be done prior to enrolment in the study and the values must be in the following ranges:

- Haemoglobin >10 g/dL;

- Platelet count >150/mm3;

- Absolute neutrophil count (ANC) >3000/mm3

- Creatinine clearance>60 mL/min

- Liver function tests

4. Females between the ages of 18 and 70 years.

5. Ability to understand and the willingness to sign a written informed consent document.

6. Eastern Cooperative Oncology Group (ECOG) score of not more than 2.

7. Participants of childbearing potential must have a negative urine or serum pregnancy test prior to enrolment and use an effective form of contraception (e.g. barrier contraception, highly effective hormonal contraception).

8. At the investigators' discretion, participants must be suitable for treatment with radical intent using concurrent chemotherapy and pelvic radiation. Subjects who undergo emergency RT in the form of brachytherapy for haemostasis, prior to enrolment will be allowed to be screened and enrolled provided they meet all other eligibility criteria.

9. Life expectancy of greater than 12 months.

10. Participants must have a body mass index (BMI) that is within normal ranges.

Exclusion Criteria:

1. Participants who have undergone hysterectomy.

2. Exclude para-aortic lymph involvement on planning CT (without contrast)

3. Patients with life-threatening AIDS defining illnesses (other than cervical carcinoma) will be excluded, as will patients with a CD4 count < 200/µL and not on ARVs.

4. Patients with acute active (such as tuberculosis or malaria), serious, uncontrolled infections will be excluded.

5. Participants will be excluded if there is evidence of resistance to antiretroviral therapy (i.e. HIV viral load > 400 copies/mL despite combination antiretroviral therapy for at least 4 months).

6. Prior invasive malignancy other than cervical cancer, diagnosed within the past 24 months, excluding in situ anal dysplasia or carcinoma in situ, non-melanoma skin carcinoma, or Kaposi's sarcoma that has not required systemic chemotherapy within the past 24 months.

7. Pregnant or breast-feeding women.

8. A medical or psychiatric illness that prevents the participant from being able to sign an informed consent or would affect the participant's ability to comply with the protocol stipulations.

9. Participants with circumstances that will not permit completion of the study or required follow-ups. For instance if travel to and from treatment site is an issue.

10. Participants with carcinoma of the cervical stump.

11. Participants with a history of cardiovascular disease manifested as

1. History of myocardial infarction

2. Unstable angina

3. Currently taking medication for treatment of angina

4. History of coronary artery bypass surgery

12. Participants with contraindications to modulated electro-hyperthermia treatment:

1. Pace makers and other implanted devices which rely on current and charges.

2. Large metal implants, such as hip replacements.

3. Inability to feel temperature in the region.

4. Inability to express or vocalise discomfort or heat at the treatment site.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Modulated electro-hyperthermia
Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH
Radiation:
External beam radiation

Drug:
Cisplatin

Radiation:
Brachytherapy
High Dose Rate

Locations

Country Name City State
South Africa Charlotte Maxeke Johannesburg Academic Hospital Johannesburg Gauteng

Sponsors (3)

Lead Sponsor Collaborator
Jeffrey Kotzen National Research Foundation of South Africa, NTP Radioisotopes SOC Ltd

Country where clinical trial is conducted

South Africa, 

References & Publications (2)

Fiorentini G, Szasz A. Hyperthermia today: electric energy, a new opportunity in cancer treatment. J Cancer Res Ther. 2006 Apr-Jun;2(2):41-6. Review. — View Citation

van der Zee J, González GD. The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia. 2002 Jan-Feb;18(1):1-12. Erratum in: Int J Hyperthermia. 2003 Mar-Apr;19(2):213.. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Local Disease Control Assessed by PET/CT using the RESIST/PERSIST criteria: complete response, complete metabolic response, partial response, stable disease, progressive disease. 6 months post treatment
Secondary Progression Free Survival To determine the progression-free survival (PFS) at 6, 12, 18 and 24 months after the last treatment date.
Determine PFS in all registered participants, regardless of completion (Intent To Treat-ITT)
Determine PFS in the subset of participants who complete the prescribed chemo-radiotherapy
24 months post treatment
Secondary 2 Year Survival Determine the overall survival at two years and the cause of death (i.e. cancer-related, HIV-related, treatment related or other). 24 months post treatment
Secondary Incidence of Adverse Events Attributed to mEHT as assessed by CTCAE version 4.0 To evaluate the adverse events that can be directly attributed to mEHT treatments. 6 months post treatment
Secondary Incidence of Treatment Related Adverse Events Attributed to Cisplatin as assessed by CTCAE version 4.0 The incidence of treatment-emergent adverse events which can be attributed to Cisplatin in each arm will be compared in order to identify any potential effect of mEHT on the frequency and severity of adverse events attributed to Cisplatin. Up to 3 months post treatment completion
Secondary Number of participants with Early Treatment Related Adverse Events as assessed by CTCAE version 4.0 The incidence of early toxicity symptoms (graded using the CTCAE version 4 criteria) associated with radiotherapy in each arm of the study will be compared to identify any potential effect of the mEHT on the incidence and severity of early toxicity. Up to 6 months post treatment completion
Secondary Number of participants with Late Treatment Related Adverse Events as assessed by CTCAE version 4.0 The incidence of late toxicity symptoms (graded using the CTCAE version 4 criteria) associated with radiotherapy in each arm of the study will be compared to identify any potential effect of the mEHT on the incidence of late toxicity in the sample group. Up to 24 months post treatment completion
Secondary Visual Analogue Scale On the EuroQoL EQ-5D-5L form To evaluate the changes from baseline value at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Visual Analogue Scale on the EuroQoL EQ-5D-5L form Up to 24 months post treatment completion
Secondary Mobility On the EuroQoL EQ-5D-5L form To evaluate the changes from baseline value at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of Mobility on the EuroQoL EQ-5D-5L form Up to 24 months post treatment completion
Secondary Self-Care On the EuroQoL EQ-5D-5L form To evaluate the changes from baseline value at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of Self-Care on the EuroQoL EQ-5D-5L form Up to 24 months post treatment completion
Secondary Usual Activities On the EuroQoL EQ-5D-5L form To evaluate the changes from baseline value at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of Usual Activities on the EuroQoL EQ-5D-5L form Up to 24 months post treatment completion
Secondary Pain/Discomfort On the EuroQoL EQ-5D-5L form To evaluate the changes from baseline value at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of Pain/Discomfort on the EuroQoL EQ-5D-5L form Up to 24 months post treatment completion
Secondary Anxiety/Depression On the EuroQoL EQ-5D-5L form To evaluate the changes from baseline value at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of Anxiety/Depression on the EuroQoL EQ-5D-5L form Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Global Health Status To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Global Health Status Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Physical Functioning To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Physical Functioning Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Role Functioning To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Role Functioning Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Emotional Functioning To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Emotional Functioning Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Cognitive Functioning To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Cognitive Functioning Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Social Functioning To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Social Functioning Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Fatigue To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Fatigue Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Nausea and Vomiting To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Nausea and Vomiting Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Pain To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Pain Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Dyspnoea To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Dyspnoea Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Insomnia To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Insomnia Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Appetite Loss To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Appetite Loss Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Constipation To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Constipation Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Diarrhoea To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Diarrhoea Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 30 for Financial Difficulties To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Financial Difficulties Up to 24 months post treatment completion
Secondary Score on the EORTC-QLQ 24 for Symptom Experiences To evaluate the changes from baseline scores at set time points (6 weeks, 3 months, 6 months, 9 months, 12 months,18 months, 24 months) of the Score on the EORTC-QLQ 30 for Symptom Experiences Up to 24 months post treatment completion
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A